Shell Asset Management CO Coherus Bio Sciences, Inc. Transaction History
Shell Asset Management CO
- $2.27 Billion
- Q3 2024
A detailed history of Shell Asset Management CO transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Shell Asset Management CO holds 17,554 shares of CHRS stock, worth $25,102. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,554
Previous 15,069
16.49%
Holding current value
$25,102
Previous $26,000
30.77%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding CHRS
# of Institutions
135Shares Held
77.9MCall Options Held
40.7KPut Options Held
50.1K-
Black Rock Inc. New York, NY11.8MShares$16.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.3MShares$16.2 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY10.4MShares$14.9 Million0.3% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$4.34 Million0.18% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.86MShares$4.09 Million0.0% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $111M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...